Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Advaxis revenue
Advaxis's revenue is $250,000.
What is Advaxis's revenue?
- Advaxis peak revenue was $20.9M in 2019.
- Advaxis annual revenue for 2021 was 3.2M, 1,180.63% growth from 2020.
- Advaxis annual revenue for 2022 was 250.0K, -92.28% growth from 2021.
- Advaxis's revenue growth from 2010 to 2022 is -50.83%.
- Advaxis has 35 employees, and the revenue per employee ratio is $7,142.
On this page
Zippi applies for you, and finds you a job.
Advaxis historical revenue
Advaxis annual revenue
Advaxis annual revenue over time
| Fiscal year / year | Advaxis revenue |
|---|---|
| 2010 | $508,481 |
| 2014 | $1.0M |
| 2016 | $4.0M |
| 2017 | $12.0M |
| 2018 | $6.1M |
| 2019 | $20.9M |
| 2020 | $253,000 |
| 2021 | $3.2M |
| 2022 | $250,000 |
How accurately did Advaxis' revenue projections match actual performance?
Advaxis annual growth
Advaxis saw the greatest revenue growth in 2021, when revenue increased by 1,180.63%.
Advaxis had the lowest revenue growth in 2020, when revenue changed by -98.79%.
Advaxis annual growth rate over time
| Year | Advaxis growth |
|---|---|
| 2014 | 97%↑ |
| 2016 | 299%↑ |
| 2017 | 201%↑ |
| 2018 | -50%↓ |
| 2019 | 244%↑ |
| 2020 | -99%↓ |
| 2021 | 1181%↑ |
| 2022 | -92%↓ |
Advaxis jobs nearby
Do you work at Advaxis?
Did Advaxis meet its revenue projections?
Advaxis financial information
| CEO | Kenneth A. Berlin |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 35 |
| Date Founded | 2002 |
| Headquarters | Princeton, New Jersey |
| Number of Locations | 1 |
| Revenue | $250,000 |
| Net Income | -$14,359,000 |
| PE Ratio | -10.01 |
| Tax Rate | -0.0% |
| Market Capitalization | $143.7M |
| Total Assets | $25,930,000 |
| Ticker | ADXS |
Advaxis jobs you might like
Advaxis financing
Advaxis received early financing of $5.0M on 2009-10-05.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Debt | $5M | 10/2009 |
| Post Ipo Equity | $7.5M | 07/2010 |
| Post Ipo Debt | $6M | 05/2011 |
| Post Ipo Debt | $1M | 02/2012 |
| Post Ipo Equity | $4.5M | 05/2012 |
| Post Ipo Equity | $26.5M | 10/2013 |
| Post Ipo Equity | $23M | 02/2015 |
| Post Ipo Equity | $25M | 08/2015 |
| Post Ipo Equity | $30M | 08/2016 |
| Post Ipo Equity | $20M | 04/2021 |
| Post Ipo Equity | $4.8M | 02/2022 |
Advaxis investors
| Investors | Security type |
|---|---|
| Sectoral Asset Management | Post Ipo Equity |
| Broadfin Capital | Post Ipo Equity |
| Adage Capital Management | Post Ipo Equity |
| Cormorant Asset Management | Post Ipo Equity |
| T. Rowe Price Group, Inc. | Post Ipo Equity |
| Sectoral Asset Management | Post Ipo Equity |
| KNIGHT THERAPEUTICS INC. | Post Ipo Equity |
| Guggenheim Securities | Post Ipo Equity |
| Jefferies | Post Ipo Equity |
| Cantor Fitzgerald | Post Ipo Equity |
Advaxis competitors
Advaxis's top competitor, Merck, earned an annual revenue of $64.2B.
Advaxis's smallest competitor is ImmunoCellular Therapeutics with revenue of $1.6M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 697 |
| Seagen | $85,008 | $2.0B | 900 | - |
| Human Genome Sciences | $70,157 | $131.0M | 1,000 | - |
| Regeneron | $85,589 | $14.2B | 9,123 | 289 |
| Merck | $90,328 | $64.2B | 74,000 | 1,708 |
| Nektar Therapeutics | $83,561 | $98.4M | 718 | - |
| Zoetis | $87,092 | $9.3B | 11,300 | 214 |
| Baxter International | $54,368 | $10.6B | 48,000 | 255 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 106 |
| Agenus | $90,894 | $103.0M | 294 | 2 |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Advaxis, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Advaxis. The employee data is based on information from people who have self-reported their past or current employments at Advaxis. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Advaxis. The data presented on this page does not represent the view of Advaxis and its employees or that of Zippia.
Advaxis may also be known as or be related to Advaxis, Advaxis Inc, Advaxis Inc. and Advaxis, Inc.